Edesa Biotech Announces Phase 2 Data Of Its Monoclonal Antibody In Hospitalized COVID-19 Patients; Critically Ill Patients Demonstrated A 68.5% Reduction In The Risk Of Dying When Treated With EB05 Over Standard Of Care